Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and tumor size reduction in untreated lesions – – First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate the second Phase 3 study in the US and Japan with Torii Pharmaceutical in mid-2026 – – Company gained alignment with the European Medicines Agency supporting a clear regulatory path forward to file for approval of YCANTH in the European Union without additional clinical studies – – Company has no outstanding debt and cash runway extended into the first quarter of 2027 – – Conference call scheduled for today at 8:30 am ET – WEST CHESTER, Pa., March 11, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced financial results for the fourth quarter and full year ended December 31, 2025.